25 plus years as a pharma focused PE fund

Jim Gale has been investing in pharma services longer than most of us have even known what a CDMO is. As the Founding Partner of Signet, he has built a fund with true staying power. Five funds. Seventy deals. A consistent philosophy. And a calm, articulate way of explaining private equity that makes you think, “Ah, so that is how it really works.”

When I sat down with Jim, a few things hit me straight away.

What I Learnt

Life is never a straight line
Jim said this early, and it stayed with me. His own path zig zagged from Arizona to Chicago to New York before he ever touched healthcare. That mindset of embracing twists and turns mirrors exactly how this sector evolves.

He explains private equity like you are sitting inside the fund
Jim’s articulation of growth equity versus traditional PE was one of the clearest I have ever heard. His “operating leverage over financial leverage” framing is brilliant and instantly usable for founders and CEOs.

Revenue per employee is the secret health metric
I loved this. Simple, revealing, and unbelievably accurate in pharma services. 

Picks and shovels is not a slogan. It is a discipline
Jim’s commitment to backing tools, services, platforms and infrastructure has stood the test of time. Twenty five years in, the philosophy still holds, even as modalities evolve from small molecules to vectors.

What I Liked

Jim is smart, successful and clearly passionate about this space. But what really stood out was his humility and calmness. He has every reason to brag. He does not.

I also loved how he opened the curtain on PE. No jargon. Just honest insight from someone who has actually built a fund and seen the full spectrum of wins and losses.

And finally, his reminder that companies and people evolve in zig zags, not straight lines, hit home. That is the entrepreneurial life.

Reflection

There is a lot of noise around private equity. Jim cuts through all of it. He shows how a great fund thinks, how decisions get made, how investors balance risk, and how you spot the difference between a good business and a scalable one.

He also made me rethink the metrics that really matter. I have spent years looking at growth, margin and EBITDA. Revenue per employee might be the cleanest health indicator I have heard in a long time.

After seventy plus deals and decades at the heart of pharma services, Jim still speaks about the sector with energy and genuine curiosity. Passion like that is rare.

Listen to the full episode
Apple | Spotify

Big thanks to our amazing sponsors Bora Pharmaceuticals, Charles River Laboratories, and Lead Candidate for supporting the pod